Gemcitabine in elderly patients with advanced pancreatic cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

365

HTML

2566

Figures (1-1)

144

Tables (1-2)

162

Sum=3237

Aug 14, 2011 (publication date) through Apr 19, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Aug 14, 2011; 17(30): 3497-3502
Published online Aug 14, 2011. doi: 10.3748/wjg.v17.i30.3497

Table 2 Characteristics of treatment in the 38 patients according to the stage of pancreatic cancer

	Metastatic	Locally advanced
Number of patients treated by gemcitabine-based chemotherapy (%)	15 (50%)	15 (50%)
Number of patients with BSC on first intention	5	3
-staff decision ECO ≥ 2	3	2
-others reasons	2 (Septicaemia, pulmonary embolism)	1 (Duodenal stenosis and deep venous thrombosis)
Median number of infusions (range)¹	n = 18	n = 7
Median number of infusions (range)¹	(1-45)	(2-13)

¹Data available for 28 patients.

Citation: Hentic O, Dreyer C, Rebours V, Zappa M, Lévy P, Raymond E, Ruszniewski P, Hammel P. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol 2011; 17(30): 3497-3502
URL: https://www.wjgnet.com/1007-9327/full/v17/i30/3497.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i30.3497